Study guide

6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting

Utah MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC

1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline

2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel

2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel

3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment

3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement

4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing

4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records

5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards

6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration

6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting

7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs

7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program

8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah

8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security

9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database

9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)

10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products

10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales

11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery

11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients

12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs

12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards

13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation

13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits

6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting

Key Takeaways Explain This Topic AI

Under Utah's Vaccine Administration Protocol, a trained pharmacist may administer listed vaccines for all appropriate ages following ACIP or state health department guidelines, and may give other vaccines under a prescription.

A pharmacist may delegate vaccine administration to a trained pharmacy intern or technician only while providing direct, on-site supervision; the delegate may not further delegate.

Utah requires every administered vaccine to be reported to the Utah Statewide Immunization Information System (USIIS) within one week of administration.

Utah's protocol sets IM epinephrine doses for anaphylaxis by weight: 0.3 mg above 30 kg, 0.15 mg for 15–30 kg, and 0.01 mg/kg under 15 kg, repeatable every 5 minutes up to 3 doses.

DOPL's 2026–27 guidance, effective September 1, 2026, lets Utah pharmacists prescribe and administer seasonal influenza and COVID-19 vaccines without a provider's prescription, but not the mRNA influenza vaccine.

Last updated: September 2026

6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting

Vaccine administration is the most common way pharmacy personnel "participate in the administration of drugs" (blueprint 2.2). Utah's framework comes from § 58-17b-102(58)(c) , § 58-17b-502(1)(i) , § 58-17b-620 , § 58-17b-627 (vaccines are a designated public-health category), R156-17b-601(3), -606, -621 , DOPL's Vaccine Administration Protocol (revised September 2023, adopted by reference in R156-17b-621(5)), and DOPL's Vaccine Administration Guidance (April 10, 2024).

Who may administer

Pharmacists who have completed the R156-17b-621 training: current BLS , didactic and practical injection training , training on the specific products, current ACIP guidelines, and anaphylaxis management .

Pharmacy interns and technicians , by delegation from a pharmacist who provides on-site, direct supervision . Technicians need the BLS, injection, and anaphylaxis training. Interns and technicians may not delegate administration to anyone else.

Each person keeps documentation of training and completes two hours of vaccine-related CE each renewal cycle after initial training (R156-17b-309; R156-17b-601(3)).

What may be administered

Under the protocol, trained personnel may administer these vaccines "to eligible patients for all appropriate ages," following ACIP or state and local health department indications and contraindications:

  • Influenza Hepatitis A Hepatitis B
  • Meningococcal Pneumococcal Varicella
  • Herpes zoster Haemophilus influenzae type b Measles-mumps-rubella
  • Human papillomavirus Tetanus-diphtheria (Td) Tetanus-diphtheria-acellular pertussis (Tdap)
  • Inactivated polio COVID-19 Respiratory syncytial virus

Other vaccines , including travel vaccines such as typhoid or yellow fever, may be administered by a pharmacist under a prescription from a licensed prescriber (or under a collaborative agreement). An authorizing practitioner who signs the protocol reviews the activities of pharmacy personnel at least annually . That authorization is valid for one year unless revoked or extended, and is not needed for vaccines given under a written prescription.

2026–27 season (DOPL announcement)

Effective September 1, 2026 , Utah pharmacists may prescribe and administer FDA-licensed 2026–27 inactivated, recombinant, and live-attenuated influenza vaccines and mRNA and recombinant-protein COVID-19 vaccines to eligible populations without a provider's prescription , using CDC clinical considerations, 2025–26 ACIP COVID-19 guidance, and AAP, ACOG, and AAFP guidance. Pharmacists may not administer the FDA-licensed 2026–27 mRNA influenza vaccine without a prescription or a collaborative practice agreement. The guidance expires if ACIP issues updated 2026–27 recommendations that CDC adopts.

Before administering

Screen the candidate or legal guardian for previous adverse events after immunization, food or drug allergies, current health conditions, recent blood or antibody products, immunosuppression, pregnancy, and underlying diseases.

The administering or delegating pharmacist reviews the vaccine and the screening information.

Inform the patient or guardian of benefits and risks and provide the current Vaccine Information Statement (VIS) . Federal law (42 U.S.C. § 300aa-26) requires a VIS before each dose of a covered vaccine.

Adverse events: Utah's protocol doses

  • Situation Protocol
  • Mild allergic reaction (hives, itching) Diphenhydramine 1.25 mg/kg orally , maximum 50 mg per dose

Suspected anaphylaxis Epinephrine IM , then call EMS immediately : 0.3 mg if over 30 kg; 0.15 mg for 15–30 kg; 0.01 mg/kg under 15 kg

Symptoms persist before EMS arrives Repeat epinephrine every 5 minutes, up to 3 doses total

Any medication given for a reaction Call EMS or have an on-site licensed independent practitioner assess the patient

Cardiac or respiratory arrest Personnel may perform CPR

The pharmacy must post an emergency plan with the local EMS number, the authorizing practitioner's number, each participant's role, and epinephrine and diphenhydramine dosing.

Reporting and records

VAERS: for adverse events, the administering or delegating pharmacist submits a VAERS report to the CDC , the authorizing practitioner , and the patient's primary care practitioner if known.

USIIS: report each administered vaccine to the Utah Statewide Immunization Information System within one week of administration.

Perpetual record: patient name; primary care practitioner (if known); vaccination date; name, address, and title of the administering or delegating pharmacist; vaccine name; manufacturer; and lot number.

Scenarios

Senior-center clinic. A pharmacy gives 45 influenza vaccines on Monday. USIIS reporting is due within one week , not 30 days.

Intern vaccinates. An intern with BLS and injection training vaccinates under a pharmacist standing beside the patient. This is permitted (direct, on-site supervision). An intern vaccinating while the pharmacist is off site is not.

Anaphylaxis in a 25-kg child. Give 0.15 mg epinephrine IM, call EMS, and repeat every 5 minutes (up to 3 doses) if symptoms persist.

Exam strategy

Vaccine questions usually turn on one of four details:

  • the reporting clock : USIIS within one week ;
  • the supervision level for interns and technicians: direct, on-site , with no further delegation;
  • weight-based epinephrine dosing and the 5-minute, 3-dose repeat limit; and

whether the vaccine is on the protocol list , in the current seasonal guidance , or needs a prescription .

Also remember the ongoing duties: two hours of vaccine CE each cycle, current BLS, and a VIS given before every dose.